Skip to main content
. Author manuscript; available in PMC: 2016 Jul 29.
Published in final edited form as: Cancer Prev Res (Phila). 2016 Feb 23;9(5):379–384. doi: 10.1158/1940-6207.CAPR-15-0300

Table 3.

Change in MD, baseline to 12-month follow-up

Placebo (n = 21) Atorvastatin (n = 23)
BIRAD category N (%) N (%) P value
No change 14 (58%) 16 (70%)
Increase 1 (4%) 3 (13%) 0.244
Decrease 6 (25%) 4 (17%)
Placebo (n = 20) Atorvastatin (n = 20)
VAS Mean change (95% CI) Mean change (95% CI)

−0.3 (−3.8–3.2) 0 (−3.9–3.9) 0.9056